priors.science/reviews/idiopathic-pulmonary-fibrosis-treatment

Idiopathic Pulmonary Fibrosis Treatment

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked

Weeklyre-scored against new papers

4 Established · 13 Likely · 3 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

SignalClaimStandingEvidence certaintyCorpus

StableMUC5B rs35705950 is the dominant genetic susceptibility locus for IPFBiomarkers PrognosisEstablished92%—

StableNintedanib slows annual FVC decline in IPFAntifibrotics EstablishedEstablished91%—

StableAcute exacerbations carry greater than 50% 90-day mortality in IPFAcute ExacerbationsEstablished88%—

StablePulmonary hypertension significantly worsens IPF survival outcomesComorbidities Pulmonary HypertensionEstablished87%—

StableNerandomilast reduces FVC decline in IPFNovel AntifibroticsLikely83%—

StableOpioid-based therapy reduces chronic cough burden in IPFCough ManagementLikely82%—

StablePirfenidone reduces all-cause mortality in IPFAntifibrotics EstablishedLikely81%—

StableBilateral lung transplant provides superior outcomes versus single lung transplant in IPFLung TransplantationLikely80%—

StableLung transplantation significantly extends survival in IPF versus medical managementLung TransplantationLikely80%—

StablePulmonary vasodilators provide limited benefit in IPF-associated pulmonary hypertensionComorbidities Pulmonary HypertensionLikely79%—

StableCorticosteroids lack RCT evidence for benefit in IPF exacerbationsAcute ExacerbationsLikely76%—

StableMUC5B rs35705950 variant paradoxically improves IPF survivalBiomarkers PrognosisLikely73%—

StableKL-6 serum levels predict IPF disease severity and progressionBiomarkers PrognosisLikely73%—

StableDynamic KL-6 change independently predicts IPF acute exacerbation riskBiomarkers PrognosisLikely73%—

StablePulmonary rehabilitation improves exercise capacity in IPFPulmonary RehabilitationLikely72%—

StableNintedanib and pirfenidone comparableAntifibrotics EstablishedLikely71%—

StablePulmonary rehabilitation benefits in IPF are not sustained beyond 6 months without maintenancePulmonary RehabilitationLikely67%—

StableAdmilparant slows FVC decline in IPFNovel AntifibroticsUncertain63%—

StableSurgical antireflux treatment does not slow IPF progressionGerd RefluxUncertain61%—

StableBexotegrast reduces FVC decline in IPFNovel AntifibroticsUncertain57%—

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely65–84%Well supported, with some gaps or indirect evidence.

Uncertain40–64%Mixed or limited evidence. Genuinely open.

Doubtful15–39%Little support; the weight of evidence leans against it.

Refuted< 15%The evidence contradicts it — confidently false as stated.

Recent signal

strengthenedNew evidence raised the certainty since the last review.

weakenedNew evidence lowered the certainty since the last review.

newA claim added to the review recently.

StableNo recent change to the standing.

Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.

Update your priors.Track this topic